Search Thermo Fisher Scientific
Immuno-Oncology Research with Next-Generation Sequencing (NGS)
Researchers are using next-generation sequencing (NGS) to better understand tumor-immune interactions and examine the immune-repertoire at an unprecedented level. Learn how NGS can be used to study tumor mutation load, clonal expansion, and TCR convergence, enabling biomarker discovery and predictive outcomes for immunotherapies in the future.
Click image to enlarge
The Cancer-Immunity Cycle
A brief explanation on the framework used to describe how the immune system recognizes and kills cancer.
What is tumor mutation load (TML)?
Tumor mutation load (TML), also known as tumor mutation burden (TMB), is a recent development rapidly becoming an independent predictor for patient stratification for response to immunotherapy. Learn more about the method and how it is applied.
Why does the immune repertoire matter?
Learn how the immune repertoire is important for cancer treatment and how NGS can be used to study the immune repertoire and improve predictive outcome for future immunotherapies by accurately calling polymorphisms, clonal expansion, and TCR convergence.